Even after rigorous propensity score matching to account for shared or confounding risk factors—such as T2DM and the use of GLP-1 receptor agonists—patients with CKD continued to demonstrate a significantly elevated risk of gastroparesis. This evidence concerns the gene GLP1R and gastroparesis.